ArticleAdvanced healthcare materials2026
Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia.
Chao He, Lingxiao Zhang, Yue Xiong, Yu Wang, Yuqing Zeng, Dandan Su, Ran Wang, Ying Li, Hongbo Chen, Fang Cheng and 1 more
Abstract read
In one paragraphArticle in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Chao HeInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, P. R. China.
Lingxiao ZhangInterdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark.
Yue XiongDepartment of Pharmacy, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, P. R. China.
Yu WangInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, P. R. China.
Yuqing ZengSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, P. R. China.
Dandan SuSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, P. R. China.
Ran WangInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, P. R. China.
Ying LiInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, P. R. China.
Hongbo ChenSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, P. R. China.
Fang ChengSchool of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, P. R. China.
Funding
European Union's Research and Innovation Program under the Marie Skłodowska-Curie 101064861Key Project of Shenzhen Natural Science Foundation JCYJ20220818102605012Natural Science Foundation of Ningbo Municipality 2022J273Natural Science of Guangdong Province 2022A1515012214Natural Science of Guangdong Province 2023A1515010978Open Project of State Key Laboratory of Respiratory Diseases SKLRD-OP-202303Open Project of State Key Laboratory of Respiratory Diseases SKLRD-OP-202305Shenzhen Bay Laboratory Start-Up Fund, National Key R&D Program of China 2022YFA1104900
6 · The paper itselfAbstract
Acute myeloid leukemia (AML) is a hematologic malignancy with frequent resistance to first-line cytarabine-based chemotherapy, primarily driven by heightened mitochondrial function. Here, we develop a copper-doped nano-aluminum adjuvant (CuNA) to overcome this resistance by targeting mitochondrial vulnerability. Upon internalization, CuNA releases Cu
Indexed as
AluminumBiomimetic MaterialsCopperDrug Resistance, NeoplasmLeukemia, Myeloid, AcuteAnimalsCell Line, TumorCytarabineFerroptosisHumansMiceMitochondriaAluminumCopperCytarabinecopper overloadcytarabine‐resistant acute myeloid leukemiaferroptosisheightened mitochondrial functionnano‐aluminum adjuvant
Identifiers
PMID41804653
PMCPMC13206377
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390